MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Conditions: Autologous Stem Cell Transplant; Classic Hodgkin Lymphoma Interventions: Drug: Pembrolizumab; Procedure: Autologous stem cell transplant; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan Sponsors: Masonic Cancer Center, University of Minnesota Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials